Cerebral concentrations of phenylalanine (PHE) were measured by means of quantitative in vivo IH MR spectroscopy in 8 adult patients treated early for phenylketonuria type I. A 1.5-Tesla routine magnetic resonance scanner, localization sequence with short echo time (20 ms), and a fully automated data processing scheme were used. Baseline plasma PHE concentrations were 1.04 (0.70-1.39) mmol/L PHE with concurrent brain PHE concentrations of 0.27 (0.13-0.41) mmol/kg of wet weight resulting in a plasma/brain ratio of 4.12. Plasma and brain concentrations correlated significantly (Kendall T b = 0.91, P < 0.01). During an oral load with a single dose of 100 mg L-PHE per kg of body weight in four patients, plasma levels steeply increased. Concurrent brain PHE increase was less steep, was significantly delayed , and still continued up to 20 h postload. Despite the proven rise in plasma and brain concentr ations of PHE, neuropsychologic examinations revealed no impairment of attentional and fine motor abilities from preload up to 20 h postload. tPediatr Res 38: 657-663, 1995) Some 40 Y after its first description (1), the PHErestricted diet for pati ents with PKU is still an out standing example of the successful treatment of inborn errors of metabolism. Despite the overall favor able outcome compared with untreated patients, open questions rem ain and new problems arise. 1) The influence of the strictness of the diet on outcome has been demonstrated clearl y (2), but it is still uncl ear why some patients with norm al outcome see m to be "protected," in spite of adhering to no diet at all (3), where as other patients on diet show a decline in e.g . IQ. 2) A rever sible impairment of cognitive function and EEG Received February 27, 1995; accepted May 11, 1995 activit y has been dem onstrated during PHE challenges (4). The decre ase in performance was , however, onl y weakl y relat ed to the total increase of plasma PHE , dem onstrating an intcrindividuall y variable sensitivity to PHE. 3) Neurologic symptoms have been observed in adult pati ent s off diet (5), which were partly reversible after reinstitution of a PHE-restr icted diet. In thes e, but also in neur ologicall y unaffec ted PKU patients, white matter chan ges have been obs erved in MRI (6). Lowering plasma PHE levels improved changes in some case s.
Abbreviations PHE, phenylalanine CSF, cerebrospinal fluid IQ, intelligence quotient IDC, index of dietary control MR, magnetic resonance MRI, magnetic resonance imaging IH MRS , proton magnetic resonance spectroscopy NMR, nuclear magnetic resonance PKU, phenylketonuria ROI, region of interest sqrt, square root T, Tesla YEP, visual evoked potential WAIS·R, Wechsler adult intelligence scale (revised version) TE, echo time TR, relaxation time activit y has been dem onstrated during PHE challenges (4) . The decre ase in performance was , however, onl y weakl y relat ed to the total increase of plasma PHE , dem onstrating an intcrindividuall y variable sensitivity to PHE. 3) Neurologic symptoms have been observed in adult pati ent s off diet (5) , which were partly reversible after reinstitution of a PHE-restr icted diet. In thes e, but also in neur ologicall y unaffec ted PKU patients, white matter chan ges have been obs erved in MRI (6) . Lowering plasma PHE levels improved changes in some case s.
In all areas mentioned, PHE and its impact on brain morphology and function seems to be a key explanatory factor. Access to a comp artment "closer to the brain" is possible by lumbar puncture, although in otherwise healthy patients it is ethically questionable. Using an animal model of hyperphenylalanin emia, Avison et at. (7) were able to show that PHE was detectable by 1H MRS in the brains of rabbits in vivo. Post-658 PIETZ ET AL. mortem measurement of brain PHE levels correlated closely to the in vivo concentration estimated from 'n MR spectra .
Mod ern methodologic approaches in MRS mak e it possible to go beyond concentration estimations via peak ratio s (8 -10) and to quantitate metab olites in molar concentrations. IH MR spectroscopy thus offers a new approach for measuring brain PHE concentrations directly and nonin vasivly. The aim of our stud y was therefor e 1) to inves tigate in vivo the plasma/brain corr elation of PHE concentrations in PKU patients by means of locali zed lH MRS , 2) to exa mine the dynamics of PHE influx into brain tissue during an oral load with L-PHE, and 3) to corr elate brain PHE concentrations to brain function during the load.
METHODS
Eight (1 wo man, 7 men) patients with PKU type I (PHE > 1200 mmol/L on a normal diet) were included. Mean age was 23 (21) (22) (23) (24) (25) (26) y. Diet onset was <2.5 mo. Plasma PEE was determined by gas column chromatography twice monthly up to 12 y of age and monthl y thereafter. According to the procedure of other outcome studies (2, 4) , for subsequ ent 6-mo periods the medi an of all PHE values was calcul ated. An IDCplasma was calculated as the mean of all o-mo-medians up to 12 Y of age. Clinical evaluation included IQ (German version WAIS-R), rout ine EEG (10/20 system), checkerboard YEP , and a standardized neurologic investigation. None of the patients had any history of other factors disturbing brain developm ent. Data of 13 (5 wom en, 8 men) health y volunteers with a mean age of 27 (19-47) y served as basis for the calculation of ave raged normal spect ra.
PHE plasma levels during this stud y were determined enzymatically (Ouantase", PHE assay, Porton Cambridge, UK). In four male patients an oral PHE load was performed. A single dose of 100 mg of purified L-PHE/kg of body weight was given along with a small meal rich in carbohydrates. After the load patients were monitored for 2 wk until plasma PHE levels were back in their usual range.
Before and 20 h after the PHE load, patients underw ent a neuropsychologic exa mination. A sus tained attention test (Dot Pattern Exercise) from a computerized neuropsychologic test battery (11) was used to evaluate the effects of the PHE load on concentr ation ability. Mean series time (ST) of this test gives informati on about th e spe ed of information processing, whereas the SD (SD ST) measures the stability of performance. Patients then performed four tests of fine motor abilities (12).
1) "St eadin ess" measures static tremor. The contacts of a stylus to the rim of a small hole are regist ered (N errors). 2) The "Maze" task measur es dynamic tremor and eye-hand coordination. Subjects run a stylus throu gh a metal maze (N errors and time errors). 3) "Sticks" is a pegboard test. Perform ance time is recorded (time). Poor coordin ation and low speed impair performance. 4) "Pursuit rotor " is a task to determ ine visual-motor performance. Lost contacts betwe en a mov ing rotor and a contact pencil are regist ered (time error) .
To estim ate white matter changes and to guide MRS localization, PKU patients we re examined by standard cran ial MRI including spin-echo T'l-weigh ted (TR 660 ms, TE 20 ms), proton densit y and T2-weight ed (TR 2400, TE 20, 80 ms) images. Whit e matter changes were rated as discrete (restricted to parieto-occipital periventricular white matter), moderate (extending to subc ortical region s) or severe (inv olving frontal and temporal lobe s as well).
Localized proton MR spectra were acquired on a 1.5-T GE Signa routin e MR sca nner in two settings . In setting A (patient nos. 1-8) a standard quadratur e head coil was used. Spectra we re acquired from a large voxel placed in the midlin e right above the ventricular system involving suprave ntricular white and gray matter of both hemispheres (typically 60 X 70 X 20 mm). In setting B (patie nt nos. 1 and 4-8) a surfac e recei ve coil (diameter 13 ern) was used. Spectra were acquired mainl y from periventricular white matte r in parietal and occi pital lobes (typi cally 30 X 30 X 25 mm). Usual acquisition parameters were: PRESS sequence (Bottoml ey PA 1984 U.S. patent 4 480 228) with outer volume suppression, wat er presaturation, and phase rotati on (13) , TE = 20 ms, repetition period TR = 3 s, 128-512 averages, 2048 data points. For the determination of different brain compartments and wa ter refer encing, a series of separa te record ings with different echo times, but no water suppression was acquired (9) .
The fully automatic data pro cessing scheme used to quantitate the PHE sign al is described in detail elsewhere (15) . Only the basic steps shall be alluded to here. Due to underlying baselin e peaks in the downfield portion of the normal cerebral MR spectrum, the singlet-like peak of the phenyl protons of PHE at 7.37 ppm was determin ed in difference spectracalculating patient spec tra minu s baseline spectrum average d from health y controls. Absolut e PHE tissue levels were determined using the intensity of the brain tissue water signal, obtained from a three compartment model wit h brain tissue wa ter, CSF , and structural mat erial as constitu ents (9) . Alth ough the displayed spectra were scaled by tissue water only, PHE concentrations were obtained taking into account PHE signal contribut ions from CSF and blood.
CSF concentrations we re calculated from plasma concentration according to a plasma to CSF ratio of 4.15, which was derived from the literatur e, calcul ating a weighted mean from the CSF data of 75 PKU patients (15) . Wh ether PHE from blood is NMR visible or not, is a prio ri unclear. Motion as well as different relaxation characteristics may render it unobservable. The loading experiments in this study gave insight into this question. Wh en calculating brain PHE concentrations in the experiments with high nonequilibrium plasma PHE levels, a correction for PHE signal contributions from blood (~5 % relative cerebral blood volume) yielded the bizzarre result that in all of the four patients brain PHE levels would initially have dropped after the intake of L-PHE. There is no plausible physiologic expl anation for this, and it is more likely that PHE from blood is not or only partially NMR-visible. All results in this study we re therefore derived, assuming PHE from blood to be undetectable. Beca use PHE concentrations in patie nts are derived from difference spectra (patient minu s control), the norm al cerebral PHE concentration in healthy sujects, reported to be as low as 0.05 mmo l/L (21, 22) , was added to the calculated PHE concentr ations in patients.
(T b = 0.91, p < 0.01) (Fig. 2) . The mean ratio of plasma PHE to brain PHE was 4.12 (3.23-4.95). Plasma/brain PHE ratios were in the same range for very different plasm a PHE concentrations between 0.70 and 1.4 mmol/L and independent of plasma PHE values under steady state conditions. Spectra acquired with the surface receive coil (setting B) lead to somew hat higher conce ntrations (Table 2) 
Measurements und er steady state conditions
Clinical data. Baseline plasma PHE levels of all patients were in their usual range before the start of the study. Four patients (nos. 3, 4, 6, and 7) were still on a PHE-restricted diet, four patients (nos. 1, 2, 5, and 8) were off diet. The neurologic investigation revealed no abnormal signs except discrete intention tremor in patient no. 6. Altho ugh all patients were treated before 2.5 months after birth, IQs in adult age ranged widely. For the 8 patients IDCplasma correlates significantly with IQ in adult age (Tb = -0.79, p < .05). In all eight patients T2 weighted images revealed patchy, nonspace-occupying white matter changes most prominent in the parieto-occipit al lobes.
Further clinical data are listed in Table 1 .
1H MR spectroscopy. The upfield portion of MR spectra revea led no apparent abnormalities with respect to the concentrations of the standard metabolites N-acetylaspartate, (total) crea tine, choline, myo-inositol and glutamine plus glutamate when comp aring patients and controls (Fig. 1) . In all difference spectra from patients (minus control), a peak of primarily unknown origin was identified in the downfield portion of the spectrum at 7.37 ppm with both settings. The solution spectrum of PHE features a strong peak at the same chemical shift (Fig.  1) . The excess peak in the patient 's spectra can therefore be attributed to the phenyl protons of PHE, whereas the a and {3 protons of PHE cannot be identified due to their small amplitudes. All spectra were transformed automatically to absolute tissue concentrations of PHE according to the described data processing scheme ( s) ) is normally distributed. The study was approved by the ethical commit ee of the University of Heidelberg. All subjec ts included gave informed consent. ratio of PHE taken from our study to form an "IDCbrain'" A reanalysis for the ratios derived from setting A revealed that the correlation "IDCbrain X IQ" was reduced to T b = -0.64, (p < 0.05). For setting B, IDCbrain X IQ was reduced to T b = -0.47 (NS). Thus, an influence of the individual plasma/brain ratio of PHE, taken from our MRS study in adult life, on the correlation of "IDCptasma X IQ" cannot be confirmed.
DISCUSSION
Dynamic measu r ements using an oral load of L-PHE Clinical data. The oral load with 100 mg L-PRE/kg of body weight in patient nos. 1-4 led to a steep increase of plasma PHE (Fig. 3a) . Only in patient no. 1 was plasma PRE determined in short intervals immediately after the start of the load. In this patient a maximum of plasma PRE was reached 1. 1H MRS. The increase of plasma PHE led to an increase of the PRE peak area at 7.37, whereas the other parts of the spectra remained unchanged. In setting A the increase was confirmed from start to 5 h postload as well as from 5 to 20 h postload (Figs. 3b and 4) . The increase of brain PRE concentrations from preload to 5 h postload was less steep (26%) compared with the increase in plasma PHE (64%). Brain PHE measured by IH MRS continued to increase significantly from 5 h postload up to 20 h postload , whereas plasma PRE had already decreased . The total increase of brain PHE from preload to 20 h postload was 54% (from 0.24 to 0.37 mmol/kg PHE). According to the different kinetic characteri stics of brain PHE influx and plasma PRE increase, plasma/brain ratios increased during the load from baseline preload measurement (3.97) to 5 h postload (5.24) and then decreased again 20 h postload (3.91). Brain PHE determinations using setting B during the loading experiment (patient nos. 1 and 4) led to comparabl e results with a 24% increase of brain PHE from preload to 5 h postload in comparison to a 72% plasma PHE increase . The total increase of brain PHE from preload to 20 h postload was 31% (from 0.32 to 0.58 mmol/kg PHE). The course of plasma/brain ratios during the load was comparable to setting A.
Neuropsychologic examinations. The neuropsych ologic examination and motor tasks performed during the load did not reveal any significant change in any relevant variable of these tests. The data of the sustained attention task and the tasks for fine motor abilities remained stable from preload baseline examination to the examination 20 h postload (Table 3) . Also, patients did not complain of any discomfor t or impairmant of vigilance along with the PHE challenge.
We were able to demonstrate, that it is possible to detect and quantitate brain PHE concentrations by 1H MRS using a clinical routine MR scanner at plasma levels, which are usual in patients with PKU. The most noteworthy and promising aspect of the current report, however , is that localized IH MRS Ratio' (plasma/brain) 
.5 ,-------------------,
• For the calcu lation of ratios brain tissue concentrations were transformed to mmol/L according to a brain tissue density of 1.05. also allow s the investigation of the tem poral course of PRE entry into the brain after an oral PRE load. Because conce ntrations of PR E in PKU patients are below the detection limit for stan dard IH MRS exa minations, it was necessary to ada pt special acq uisi tion parameters discusse d in detail in Kreis et al. (15) . T hey comprised a PRESS localization sequence w ith shor t echo time and tw o alterna tive settings in terms of receive coi l and ROI size. Setting A (large supraventricul ar ROI , sta ndard head coi l) is preferable with respe ct to signal to noise ratio. Setting B (smaller ROI , surface coil) is adva ntageous w ith resp ect to size and reproducibility of line widths. In our stud y, sligh tly different con centrations we re derive d from the two settings (see Table 2 ). Regi onal concentra tion gradients, different compartme ntation , as well as erro r a) of measure ment, may have con tributed to these differe nces .
Comparisons of the upfield portion of the patient ' s as well as the downfie ld portion of the baseline spectra indi cates that this apparent regional variation ma y be genuine and not an artifact of differi ng acq uisition parameters. Th e averaged spectrum of healthy controls features a peak of un known or igin with a maximum at 7.30 ppm near the point of interest at 7.37 ppm where PRE is detected . Because bra in PR E conce ntra tions in healthy controls are report ed to be as low as 0.05 mm ol/kg of wet weight (16 , 17) , this baseline peak cannot be due to free PRE. Calculati ng PR E peak areas w ithou t correcting for this pea k will ove restimate PRE concent rations. A maj or point of our approach to quantitate PRE in vivo was the refore to use difference spe ctros copy (18) with identical acquisition and data processing for pat ients and matched hea lthy controls.
A sec ond important issue is the utilization of an objective, fully autom atic, and operator-unbiased data processing and quantitation scheme, taki ng cerebral co mpartme ntat ion into account also . Both ROls studied we re separated into two compartments. T he first co mpartment rep resents brain tiss ue composed of intr a-plus extracellular space w ith the vo lum e of extracellul ar space betwe en 15 and 20% (19) . The second com partment is due to CSF w hich, in controls, accounts for about 5 % of the voxel volume in setting A (2.5% in sett ing B). In PKU patients this space is about double in both settings , whic h means that there is an addi tional CSF-like spa ce in patie nts. An enlargement of CSF space by cortical atrophy is one explanation, partic ularly for set ting A which incl udes sulci and interhemis pheric space. Th e voxel in setting B inclu des MRI-visible white matter changes. It seems therefore mos t likely that additional wa ter wi thin whi te matter of PKU patients con tributes to this CSF-like space as well to the hyperintensities in T2-weight ed images observed in all eight patients. As the tru e concentrat ion of PRE in CSF is not kno wn and cannot be measured reliably by MRS , our correction for PHE from eSF in the voxe ls, based on the plasma PHE concentration, impli es some uncertainty. Fairly consistent values for the ratio of plasm a to CSF PHE are, however, reported in the literature as sum mariz ed by Kreis et at. (15) . In addition, because brain concentration s determined by 1 H MRS and estima ted eSF concentrati ons differ little, the correction for PH E from eSF leads to maximal changes on the order of only a few percent. However, due to the different water content in brain tissue and eSF, it is still imperative to distingu ish between the two comp artmen ts when water is used as the internal sta ndard for quant itation, and an appreciab le eSF space is included in the ROJ. A lso, it has to be menti oned that in the ora l loading experiments whic h lead to nonsteady state situations, the eSF corr ection may be more important, but also leads to somewhat larg er unc ertainties in quantitation. Brain tissue conc entrations of PHE determined in our study by lH MRS are lower than those reported by Avison et at. (7) for an animal model of PKU . They report a ratio of serum to brain concen trations determined by IH MRS in vivo of 2.65, but differences in MR methodology, the referencing to crea tine, as well as uncontrolled effects of the administration of o -methylphenylalanine to the integrity of the blood brain barrier and brai n metabolism have to be taken into account. The only data on PHE determin ations by means of in vivo IH MRS in humans were presented by Novotny et al. (20) . In their study PHE was detectable in five adult patients off diet at plasma concentrations above 1.4 mmollL using a 2.1-T magnet. PHE was calculated in relatio n to an assumed creatine concentration of 9.0 mmol/L. Johannik et al. (21) did not detect a PHE peak in PKU patients which is well explained by their acquisition parameters . Brain PHE levels determined by 1H MRS in our study seems to be in some contrast to the data reported from autopsy of untreated PKU patients by McKean (22) , which we re in the range of 0.85 to 1.0 mm ol/kg of wet we ight. Data from plasma are not available, but usual plasma levels of untreated PKU patients are in the range of about 1.5 to 2.0 mmol /L PHE. For comparison with our study, it has to be taken into account that PHE values from autopsy material may over estim ate in vivo concentrations becaus e of autolysis, which was shown for non -PKU co ntro ls w hen co mpa ring fr esh bi op sy (0 .05 mmol/kg of wet weight PHE ) and autopsy materi al (0.13 rnmol/kg of we t weight PHE) (16, 23) . Under these assumptions our results fit well with the biochemically determined PHE values from autopsied brains of untreated patients. It is notewor thy that region al differences for cerebral PHE concentrations we re found in controls (23) .
To our knowledge, the present study comprises the first report of dynamic data regarding the influx of PHE into human brain in vivo. It was shown that the influx of PHE through the blood-brain barrier continued during our whole observ ation period. In an animal study reported by McKean et al. (24) , brain PHE showed a much steeper incr ease after loading rats with L-PHE intraperitoneally. The plasmalbrain ratio incre ased from a baseline value of 1.1 to 4.35 at 30 min postload and then decreased again to 2.4 at 60 min postl oad . It is not clear to what extent blood in brain vessels con tributed to these results, and there are no results for long er observ ation times. Experim ents with much longer observation times in PKU patients could therefore further clarify the dynamics of PHE influx into brain tissue as we ll as the efflux after lowering blood levels of PHE .
With respect to the ratios derived from setti ng A, the brain concentr ation of our eight patients would vary from 0.20 to 0.31 mmol/kg of we t weight PHE for a given plasma concentration of~1.0 mmol/L PHE , which are substa ntial differences. Our expectation that these interindividual differences in pIasrna/br ain ratios would play a clinicall y relevant role by enhancing or reducing the cerebral toxicity of a certain plasma PHE level could not be verified in the patie nts studied. The correlation between long-term PHE levels during the first 12 y of age and IQ in adult life was reduced when taking the individ ual plasmalbrain ratio into acco unt. Due to the small number of patients on which this cor relation is based , this resu lt is only preliminary. Also, it is know n that the functional properties of the blood brain barrier are not a stable attribute over time. The influx of PHE into brain tissue may change dramatically during development (17) . This was proven in an animal model (25) as well as by the determination of PHE in cord blood and brain tissue of aborted human PKU fetuses (26) , in which a plasmal brain ratio of about 1 proves a higher influx of PHE into brain. As there is wide intraindividual variation in the course of time there may be also interindividual variation leading to relatively "high" plasmalbrain ratios in adult life in patients with "low" plasma/brain ratios during childhood and vice vers a. Thus, it may be incorrect to relate data from adult life to childhood, which is, regarding the brain damage by PHE , the more important period.
IH MRS also promis es to become a tool in the investi gation of the effects of elevated PHE after terminating dietary treatment. Several studies have shown that the concurrent PHE level may have a "toxic" effect on cognitive functions. An impairment of brain function can also be detected by electroencepalographic methods, usually noted as a slowing of background activity in spectra l analysis (4). We did not detect any deterioratio n in attentiona l and fine motor performance for our patients after a single loading dose of I. -PHE, although plasma and brain concentrations were well above the baseline levels. A simple explanation for this result is lacking, but it seems possible that cognitive impairment may be tied to prolonged periods (4) of elevated PHE. Little is known, however, about transport of amino acids in extracellular space, the uptake and utilization by glial and neuronal cells, trans-and intracellular transport after an abrupt change of concentrations, as during our PHE load (27) . It should also be noted that the changes of brain metabolism due to elevated PHE levels and its effects on neuronal function are still largely unknown (28) .
Sum marizing our first results in the use of IH MRS , we find that PRE can be quantit ated in vivo by localized 1R MRS in concentrations which are common in adult PKU patients. Although plasma as well as brain tissue concent rations of PHE increased substantially in a loading experi ment, we did not detect any impairment of attentional and fine motor abilities. It was show n that the different kinetics of PHE in plasma and brain tissue can be traced by IH MRS and may give new insights into the relation betwee n brain PHE concentrations and impairments of brain function.
